Disease site number was not prognostic in a low-risk Hodgkin lymphoma combined modality trial: revisiting PHC HOD90.
Angela M FeracoYiwang ZhouYing ZhengLianna J MarksAlison M FriedmannHoward J WeinsteinMichael P LinkJamie E FlerlagePublished in: Blood advances (2023)